IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

QUANTUM DOT-BASED SPECTROSCOPY FOR VONOPRAZAN IN NANOMEDICINE APPLICATIONS

NIVATHRA V [1]* ,SUDHARSAN K [2], SREENATH V [3], PADHMA SHRI BABU [4]

[1]* Assistant professor, Department of Pharmaceutical Chemistry and analysis, [2,3,4] B. Pharm students

School of Pharmaceutical sciences, Vels Institute of Science Technology and Advanced Studies, Chennai, Tamilnadu, India

Abstract

The gastrointestinal disorders associated with acid such as gastroesophageal reflux disease, peptic ulcer disease and infection of Helicobacter pylori still remain to have significant clinical burden on a global scale. Vonoprazan a potassium-competitive acid blocker is a great improvement over the traditional proton pump inhibitors due to its quick onset of action, its stability as an acid, and its ability to maintain gastric acid inhibition. However, its utilisation is limited due to all challenges related to formulation optimisation, focused delivery, and real-time monitoring of therapeutic effects. Nanotechnology and, specifically, quantum dot (QD)-based systems have currently made new strides in addressing these shortcomings. Quantum dots are nanoscale semiconductor materials which can be used as drug carriers and spectroscopic probes as they are size-tunable to give fluorescence, exhibit high photostability, and give a high signal. Vonoprazan conjugated with QD based nanocarriers improves stability of drugs, allows targeting and controlled delivery of drugs to gastric mucosa and real-time basis monitoring of drug loading, distribution, and release. QD -based spectroscopy provides better sensitivity, spatial resolution and theranostic capabilities in comparison to the traditional methods of analysis. In this review, the pharmacological profile of Vonoprazan, the use of quantum dot based nanomedicine to enhance drug delivery, and the use of spectroscopic methods to assist in the real-time analysis and imaging guided treatment are critically reviewed. Overall, quantum dot nanotechnology and spectroscopy integration has a potential to form an effective theranostic strategy to potentiate the efficacy, safety, and personalisation of Vonoprazan treatment in acid-related gastrointestinal diseases.

Keywords: gastroesophageal reflux disease, Helicobacter pylori, Nanotechnology ,quantum dot, theranostic.

I. INTRODUCTION:

Unlike PPIs, Vonoprazan acts as a direct (and reversible) inhibitor of the gastric H +/K+ -ATPase by binding potassium ions at the luminal binding site and, therefore, producing a quick and Gastrointestinal conditions associated with acid, such as gastroesophageal reflux disease (GERD), peptic ulcer disease (PUD) and Helicobacter pylori-related diseases remain one of the most significant clinical issues globally**[1]**. Inhibition of gastric acid secretion is the essential part of the management of such disorders and proton pump inhibitors (PPIs) have been the mainstay of treatment over a number of decades**[2]**. However, lack of clinical utility of PPIs include long onset of action, acid instability, short

plasma half-life and high inter-individual variability due to cytochrome P450 (CYP2C19) genetic polymorphisms**[3]**. Such inadequacies have inspired the advancement of other treatment interventions that offer more rapid, reliable and permanent acid suppression**[4].**

Vonoprazan being a potassium-competitive acid blocker (PCAB) is a significant development in acid-suppressive treatmentstrong acid inhibition with a first dose**[5]**. Its stability to acids and independence of pH upon activation reduces the variation in therapy and eliminates a number of the limitations to conventional PPIs**[6].** Irrespective of these advantages, Vonoprazan delivery, monitoring and clinical translation is a subject of ongoing research**[7]**.

The recent advancement in nanotechnology, specifically the production of quantum dots (QDs) has provided an opportunity to improve the use of drugs delivery and therapeutic monitoring**[8]**. QDs are nanoscale semiconductor materials which are characterized with high fluorescence, size-tunable optical properties and excellent photostability and have thus become desirable biomedical application platforms**[9]**. Combination of vonoprazan and quantum dot based nanocarrier systems implies the possibility to enhance the stability of drugs, targeted delivery to gastric mucosa and real time spectroscopic monitoring of drug-carrier interactions and release kinetics**[10]**. Spectroscopic methods including UV-visible spectroscopy, fluorescence spectroscopy and Förster resonance energy transfer (FRET) are here in key roles towards the characterisation of these systems**[11]**. The purpose of this review is to critically analyze the pharmacological profile of Vonoprazan, use of quantum dot based nanotechnology in drug delivery, and use of spectroscopic methods to aide a theranostic platform in the advanced management of acid related gastrointestinal disorders**[12]**.



Figure 1. Mechanism of Action of Vonoprazan

1.1 Innovation and Originality of the Current Review.

This review aims to combine Vonoprazan pharmacotherapy and the use of quantum dot-based spectroscopy and theranostic nanomedicine**[13]give 4** . In contrast to the current reviews that generally pay attention to the pharmacological benefits of Vonoprazan or the overall use of quantum dots as nanocarriers in the delivery of drugs, the current article is the only one that focuses on the application of quantum dots as multifunctional platforms that permit simultaneous drug delivery, real-time spectroscopic monitoring, and bioimaging**[14]**. A particular focus is put on quantum dot -based methods of analysis such as fluorescence spectroscopy and Förster resonance energy transfer (FRET) that enable continuous and non-invasive monitoring of Vonoprazan loading, distribution, and release at a nanoscale**[15]**. This review has indicated the benefits of quantum dot based theranostic systems in providing dynamic information regarding the behaviour of drugs in a biological system by avoiding the traditional delivery based methods of theranostic systems and moving to real time monitoring and imaging guided therapy. It is an integrative approach that tries to fill the gap between pharmaceutical sciences, nanotechnology, and clinical translation, providing a prospective model of the development of precision and personalised Vonoprazan treatment**[17]**.

II. **Vonoprazan is a P-CAB whose mechanism of action is as follows**.

Vonoprazan has acid suppressive effect caused by potassium competitive inhibition of gastric H +/K +-ATPase located on secretory canalicular membrane of parietal cells**[18]**. Vonoprazan is bound directly and reversibly to the potassium-binding site of the enzyme, as opposed to the conventional proton pump inhibitors, which are administered as prodrugs and need acidic activation in the canaliculus to undergo irreversible covalent interactions with the proton pump**[19]**. This mechanism allows the inhibition of acid secretion at a fast rate regardless of the intragastric pH and removes the condition of acid activation beforehand. Vonoprazan has an acid-stable structure, which guarantees the steady bioavailability, and reversible effects lead to the prolonged inhibition of gastric acid secretion. In addition, Vonoprazan has low sensitivity to CYP2C19 genetic polymorphisms, and as a result, there is less inter-individual variability of response to therapy**[20]**. All these mechanistic properties are involved in the high rate of onset, high potency, and enhanced clinical results of Vonoprazan over traditional proton pump inhibitors**[21]**.



Figure 2. Chemical Structure Comparison

Parameter	Proton Pump Inhibitors (PPIs)	Vonoprazan (PCAB)
Mechanism of action	Irreversible inhibition of H^+/K^+-ATPase after acid activation	Reversible potassium-competitive inhibition of H^+/K^+-ATPase
Onset of action	Delayed (requires several doses)	Rapid (effective from first dose)
Acid stability	Acid-labile, requires enteric coating	Acid-stable
Genetic influence	Affected by CYP2C19 polymorphism	Minimal influence of CYP2C19
Clinical outcome	Variable acid suppression, slower symptom relief	Stronger and sustained acid suppression with improved symptom control

Table 1. PPIs vs Vonoprazan

III .Challenges and Limitations

Although the pharmacological behavior of Vonoprazan is promising and quantum-dot-based nanocarrier systems can provide a wide range of benefits, a number of challenges have to be overcome to achieve positive clinical translation**[22]**. Traditional semiconductor quantum dots are made of heavy metals (ex: cadmium or lead) which raise serious concerns about long-term toxicity, bioaccumulation, and safety to the environment. This has necessitated the emerging phenomenon of biocompatible versions or substitutes i.e. carbon or silicon quantum dots**[23]**. Moreover, the high drug loading efficiency, release kinetics, and extended stability of Vonoprazan in quantum-dot formulations are things that one would struggle to accomplish technically**[24]**. Analytically speaking, spectroscopic

methods though very sensitive require careful optimization so as to avoid signal interference, photobleaching and interpretation of fluorescence-based interactions**[25]**. Moreover, the regulatory hurdles related to the approval of nanomedicine, which include the necessity to standardize characterization procedures and carry out tedious safety assessments, make the road to the clinical use even more difficult. It is crucial that overcoming these issues with the help of rational nanomaterials design, analytical validation, and strict compliance with regulatory recommendations will be the key to the progress of Vonoprazan-based theranostic systems towards clinical implementation**[26]**.

Challenge Category	Key Issue (Brief)	Clinical Impact
Solubility issues	pH-dependent solubility; reduced solubility at neutral/alkaline pH	Inconsistent absorption and variable drug exposure
Stability concerns	Sensitivity to moisture, heat, and light; in vivo degradation	Reduced shelf-life and potential loss of potency
Bioavailability limitations	pH effects, first-pass metabolism, GI variability	Fluctuating plasma levels and variable therapeutic response

Table.2 Key Challenges Affecting Vonoprazan Therapy

3.1 FDA Indications of Vonoprazan Approved.

Vonoprazan is a potassium-competitive acid blocker (PCAB) that is licensed to treat a number of acid-related gastrointestinal disorders**[27]**. Its clinical indications are approved as:

Gastroesophageal reflux disease (GERD): Both erosive and non-erosive GERD effective due to rapid and prolonged acid suppression**[28]**. .

The therapy of the eradication of helicobacter pylori: It is also used in triple or dual therapy regimens, where it has been shown to be better in controlling intragastric pH, compared to proton pump inhibitors, and thus, increase eradication rates.

Quick Onset of action as compared to PPIs. In contrast to the traditional proton pump inhibitors (PPIs), Vonoprazan does not have to be activated by acid; it directly and reversibly blocks the enzyme H + / K + -ATPase on the luminal side. Clinical trials have shown the effect of fast analgesia, frequently after the first dose; more predictable intragastric pH regulation, even in the nocturnal period, and the decrease of variation due to CYP2C19 genetic polymorphisms. All these features make Vonoprazan especially beneficial to the patients who were found to have poor responsiveness to PPIs**[29]**.

Increasing International Acceptance and Clinical Usage. Vonoprazan was initially licensed in Japan in 2015 and later has found broad clinical use in several countries, such as Japan and South Korea. The East Asian clinical success has triggered more approvals and clinical trials in other regions of the world, thereby making global markets such as Europe and North America to draw more interest. Research is still being done to determine the safety, efficacy and possible being more effective than PPIs in wider patient groups over the long term**[30]**.

IV. Drug Delivery (Quantum Dots) Nanotechnology.

The development of drug delivery systems based on nanotechnology has received significant interest due to their ability to increase the therapeutic efficiency of pharmacological agents through enhanced stability, bioavailability and target efficiency**[31]**. Quantum dots (QDs) are a group of nanoscale semiconductor materials, which have size-dependent fluorescence emission, unprecedented photostability, and high signal intensity, which makes them especially appealing to combined drug delivery and imaging**[32]**. Applied as nanocarriers to Vonoprazan, QDs are able to prevent premature release of the drug, control release kinetics, and deliver the drug to the gastrointestinal mucosa. The aqueous stability of QDs, decrease in nonspecific interactions and increase in site-specific accumulation by surface functionalization with biocompatible polymers (polyethylene glycol (PEG) or targeting ligands) or site-specific accumulation**[33]**. In addition, the intrinsic fluorescence of QDs makes it possible to monitor the processes of drug loading, distribution, and release in real time using the spectroscopic methods**[34]**. Although traditional heavy-metal-based QDs are toxic, new biocompatible QDs such as carbon and silicon quantum dotes have better safety profiles and better translational potential. Together, quantum-dot-based

nanocarrier systems form a potentially highly successful platform of promoting Vonoprazan delivery and, at the same time, diagnostic and therapeutic integration**[35]**.



Figure 3. Quantum Dot-Based Vonoprazan Nanocarrier

Quantum Dots (QDs) can be defined as a collection of particles with specific sizes, shapes, and densities (Taylor, 2003).

Quantum dots (QDs) are size-dependent optical nanoscale semiconductor materials, which are normally 2 to 10 nm in diameter due to quantum confinement effects. Their bi-directional fluorescence with high photostability, sharp emission spectra and wide excitation wavelengths makes them better than traditional organic fluorophores in analysis and imaging purposes**[36]**. The structure QDs most typically have a semiconductor core, which might include cadmium selenide or silicon, frequently surrounded by a shell material that tends to stabilize the QDs and increase their optical properties. Functionalization of the surfaces further enhances aqueous solubility, biocompatibility and biological interactions thus making surface functionalization useful in bioimaging, sensing and drug delivery**[37]**. However, the toxicity issues relating to the heavy metal based QDs have led to the increased pace of producing safer carbon and silicon based quantum dots, which have a greater biocompatibility and high clinical translation capabilities**[38]**.

4.1 Nanoscale Characteristics of quantum dot.

Optical Property	Description	Relevance in This Review
Size-tunable emission	Emission wavelength depends on QD size	Enables multicolor imaging
High quantum yield	Strong fluorescence intensity	Improves sensitivity
Broad absorption	Excitable over wide wavelengths	Suitable for UV–Vis studies
Photostability	Resistant to photobleaching	Ideal for long-term monitoring
Energy transfer ability	Efficient donor in FRET	Enables real-time drug release tracking

Table 3;Special Optical Properties of Quantum dots (QDs).

Quantum Dots That Are Often Used in Biomedicine



Figure 4. Types of Quantum Dots Used in Biomedicine

Type of Quantum Dot	Typical Size (nm)	Toxicity Profile	Fluorescence Properties	Suitability for Biomedical Use
CdSe/ZnS QDs	2–10	High (heavy metal content)	High quantum yield, tunable emission	Limited due to toxicity concerns
Carbon Quantum Dots	<10	Low	Moderate fluorescence, excitation-dependent	Highly suitable and biocompatible
Graphene Quantum Dots	3–20	Low to moderate	Stable fluorescence, good photostability	Suitable with surface modification
Silicon Quantum Dots	2–5	Very low	Good fluorescence, biodegradable	Highly suitable for clinical translation

Table 4. Quantum Dots Used in Biomedicine

4.2 Quantum Dots vs. conventional Nanocarriers Comparisons.

Liposomes, polymeric nanoparticles, and solid lipid nanoparticles are all conventional nanocarriers that have been widely studied to deliver drugs due to their biocompatibility and ability to increase drug solubility and stability. As lipid bi-layers, liposomes can entrap both hydrophilic and lipophilic therapeutics; however, often liposomes are characterized by poor physical stability, rapid clearance and lack of intrinsic imaging capabilities. Polymeric nanoparticles allow targeted and prolonged release of drugs, but their highly complicated synthesis pathways, possible polymer toxicity and the lack of real-time monitoring features undermine their multifunctional use. Solid lipid nanoparticles are also associated with enhanced stability and biocompatibility, but characterise low drug-loading capacities and erratic release profiles**[39]**.

On the contrary, the quantum dots are versatile nanocarrier systems that combine drug delivery with real-time bioimaging and spectroscopic analysis. In comparison to the other conventional carriers, quantum dots have intrinsic fluorescence, thus allowing mapping of biodistribution, cellular uptake, and drug release to be done simultaneously without the addition of any supplementary contrast agent**[40]**. This theranostic property is special, as quantum dots can give both spatial and temporal information about drug behaviour which are not available to conventional nanocarriers. Even though the safety issues regarding heavy-metal-based quantum dots are clear, the introduction of carbonbased and siliconbased quantum dots has significantly increased their biocompatibility and translational capacity. As a result, although conventional nanocarriers are mainly used in facilitating delivery, quantum dots provide an integrated system that can be used in targeted delivery, real-time tracking, and imaging-guided therapy**[41]**.

4.3 The Constraints of Quantum Dots Fundamentals.

Despite the unique optical behavior at a certain size and excellent photostability, quantum dots have a variety of inherent limitations that limit their extensive use in biomedicine. Physicochemical properties of quantum dots, such as size, surface charge, and elemental composition, are highly sensitive to the parameters of a synthesis, which contributes to variation of batches to batches and reproducibility**[42]**. The traditional quantum dots use heavy metal including cadmium or lead, which generates the concern of cytotoxicity, oxidative stress, and bioaccumulation in the long-term. The partial understanding of the in-vivo behavior of the heavy metals, including biodistribution, metabolism, and clearance mechanisms, limits accurate risk assessment, even in the absence of heavy metal. Also, the fluorescence efficiency can be impaired by surface defects, non-radiative recombination, and aggregation in the biological media can change the optical performance. All these inherent constraints highlight the need to have controlled synthesis, highly effective surface functionalization methodologies and extensive safety and stability assessments prior to quantum dots finding their way to the clinical and pharmaceutical clinic**[43]**.

V. The Absorption Interaction of Drugs-Nanoparticle Study.

The study of absorption processes provides the background information of the relationships between drugs and nanoparticle delivery systems. In the framework of drug-nanoparticle preparations, absorption is a change in the electronic transition of a drug molecule caused by the association of the drug molecule with a nanoparticle surface or by being encapsulated within a nanocarrier. These interactions can be conveniently investigated through UV visible absorption spectroscopy, which is a commonly used method of studying complex formation, binding affinity and physicochemical stability. In case a drug interacts with nanoparticles, the changes in the absorption spectrum, including the shift of peaks in the wavelength, the change in absorbance intensity, or the broadening of bands may occur, which in turn indicate a change in the local electronic environment of the drug**[44]**.

In the case of quantum dots systems, absorption experiments can be especially instructive since quantum dots have large absorption bands and optical properties that depend on size. Interaction of drugs such as Vonoprazan with quantum dots may give rise to spectral changes that can be quantified to give evidence of adsorption, electrostatic interaction, or hydrophobic binding on the surface**[45]**. These absorption-based measurements provide qualitative and quantitative data of drug loading and drug-nanoparticle goodness without requiring drug chemical modification. In addition, absorption studies are used as a preliminary analytical method to analyze the stability of the formulation as well as forecast possible interaction before the study is advanced to spectroscopic or biological evaluations. Based on it, the UV-visible absorption analysis is a key method to characterize drug-nanoparticle interactions as well as facilitating the rational design of the nanoparticle-mediated drug delivery systems**[46]**.

5.1 Test to determine how quantum dots and drugs interact.

To understand and analyze the effects of quantum dots (QDs) on drug molecules, a wide range of experimental methods are utilized, thus explaining the binding, loading process, and stability of the resulting drug-nanoparticle complex. Such studies are critical towards the design optimization of nanocarriers and reproducible therapeutic functionality**[47]**. Spectroscopic techniques are most commonly used due to their sensitivity, ease and ability to probe the interactions at the molecular scale.

UV absorption spectroscopy is commonly used as a pre-answer in evaluating drug-QD interactions through a change in the absorption maxima, change in peak intensity, or spectral broadening during interaction**[48]**. These changes are indicators of changes in the electronic environment of the drug molecule due to the adsorption or binding to the QD surface. Fluorescence spectroscopy also complements absorption measurements by determining quenching or enhancement of emission signals that can be due to either non-dynamic or dynamic interactions, or energy transfer, or alterations in

microenvironment polarity. The FRET experiments can be particularly useful when the QDs are used as fluorescent donors and drugs or probes act as acceptors, which will make it possible to monitor the dynamics of drug loading and release at the nanoscale in real time**[49]**.

Besides spectroscopic methods, physicochemical characterization methods, including dynamic light scattering (DLS) and zeta potential analysis are used to determine the variability of particle size distribution and surface charge after drug loading and hence offer indirect evidence of interaction and complex stability. HPLC and liquid chromatography-mass spectrometry (LC -MS) methods are used to determine the degree of efficiency in drug loading, encapsulation stability, and possible degradation products. Combined, these complementary experimental strategies provide a total insight into quantum dot-drug interactions, thus informing the rational generation of nanomedicine platforms to achieve improved drug delivery and therapeutic monitoring**[50]**.



Figure 5. UV–Vis Spectroscopic Interaction

5.2 Fluorescence Resonance Energy Transfer (FRET) is one of the techniques of tracking the state of Vonoprazan. Released.

Fluorescence Resonance Energy Transfer (FRET) represents an effective means of analysis with the capability to probe the state and release dynamics of pharmaceutical agents on the nanometer scale. FRET can be induced in quantum-dot delivery systems where the quantum dot is used as an energy donor and the drug molecule, or a fluorescent probe that has been conjugated to it, serves as an energy acceptor. When a separation between the donor and acceptor ranges between 1-10nm, optimum energy transfer is experienced. In the case of Vonoprazan that was encapsulated into quantum dots, sharp FRET signal will indicate effective loading and close proximity between the particle and the nanocarrier. The further the drug gets released, the longer will be the distance between the donor and the acceptor, the lower will be the FRET efficiency that should be reflected in the observation of the changes in the intensity of the fluorescence or the wavelength of the emissions**[51]**. Such changes enable the real-time and non-invasive monitoring of Vonoprazan release kinetics at physiological conditions. The superb sensitivity and sub-nanometer resolution properties of FRET make it especially useful in understanding drug-nanoparticle interactions, unravelling release mechanisms, and determining formulation stability and, consequently, form the basis of theranostic platforms designed to facilitate controlled drug delivery**[52]**.

5.3 Estimation of the distribution of Vonoprazan in nanocarriers by spectroscopic mapping criterion:

Spectroscopic mapping methods provide a solid platform on which to understand spatial localization of drug molecules in nanocarrier structures**[53]**. In the framework of Vonoprazan-loaded quantum dots, the given mapping simplifies the visualization of the drug distribution across or within the carrier matrix, as well as a quantitative analysis. Mapping, particularly by the use of fluorescence, is particularly beneficial because the inherent fluorescence characteristics of quantum dots allows assemblies of drug-nanocarriers to be tracked with high-resolution without intensive labeling. Spectroscopic mapping allows distinguishing between encapsulated and surface-bound Vonoprazan

moieties by comparing the intensity of fluorescence and emission wavelength of multiple spatially resolved regions. Changes in fluorescence signals are an indication of differences in local concentration of drugs, strength of interactions, and polarity of the microenvironment**[54]**.

Spectroscopic mapping, when used together with confocal fluorescence microscopy or hyperspectral imaging, gives accurate information as to the heterogeneity of drug distribution at the nanoscale**[54]**.

Moreover, absorption and fluorescence mapping may be used to track changes in drug distribution in a variety of physiological conditions, including changes in pH, ionic strength, or enzyme activity, to provide ideas on formulation stability and release dynamics. The above mapping strategies are all used to arrive at an overall view of Vonoprazan loading efficiency, spatial homogeneity, and release behavior, which in turn can be used when designing and optimizing quantum-dot-based nanocarriers to develop a targeted drug delivery and theranostics platform**[55]**.

5.4 Stability of Vonoprazan in biological fluids analysed by spectroscopies of QDs:

Vonoprazan stability in the biological fluids is a critical determinant to its therapeutic efficacy, pharmacokinetic attributes. The use of quantum dots in spectroscopic methods provides an efficient and sensitive method of drug stability monitoring under physiologically realistic conditions, such as gastric fluid, intestinal fluid and plasma**[56]**. Based on the strong fluorescence properties of quantum dots, the subtle chemical state changes in Vonoprazan can be detected by the changes in absorption spectrum, fluorescence intensity, or energy transfer efficiency.

In the case of Vonoprazan linked to the functionalized quantum dots, spectroscopic tracking can be used to allow real-time evaluation of drug integrity in complex biological systems. Fluorescence signal deviations can indicate drug degradation, desorption off nanocarrier surface, or modified interactions with biomolecules (i.e. proteins and enzymes in the fluids). In this respect, the FRET system is one of the most informative because energy transfer efficiency can decrease as an indicator of drug dissociation or structural alteration with time**[57]**.

Furthermore, quantum-dot-assisted spectroscopy makes it possible to conduct comparative analysis of the stability of Vonoprazan in different pH conditions and in the enzymatic settings, which provides the information about the formulation stability and protective effects of nanocarrier encapsulation. These analytical tools aid optimization of nanocarrier design and increase the predictive validity of in vivo activity and can be used to develop stable and effective Vonoprazan-based nanomedicine preparations**[57].**

Technique	Primary Application	Information Obtained	Advantages	Limitations
UV–Vis Spectroscopy	Drug–QD interaction	Absorption shifts, binding evidence	Simple and rapid	Low sensitivity
Fluorescence Spectroscopy	Imaging and binding studies	Emission changes, quenching	Highly sensitive	Susceptible to photobleaching
FRET	Drug release monitoring	Real-time nanoscale interactions	Enables dynamic monitoring	Requires careful probe design

Table 5. Analytical Techniques

VI.QD-Based Systems of Drug Delivery: As Encapsulation and Controlled Release.

Quantum-dot (QD) systems of delivery have taken the form of a universally applicable system of encapsulation and programmed release of therapeutic agents. Encapsulation is commonly done by physical adsorption, electrostatic, covalent conjugation or entrapment by polymer. Such approaches enable effective loading of drugs and also protect the active molecule against untimely degradation and adverse interaction with the biological milieu. In the case of Vonoprazan, the surface-functionalised

QDs are capable of providing stability, high solubility at physiological conditions, and targeted delivery of the surface-functionalised QDs to the gastric mucosa**[58]**.

The nature of drug-nanocarrier interactions and physicochemical characteristics of the surrounding environment control the controlled release of QD-based systems. Parameters like pH, ionic strength, enzymatic activity, and polymer-coating composition are critical parameters in which release kinetics are modulated. Gastric pH varies or responds to certain biological triggers QD systems Stimuli-responsive QD systems are able to provide specific control over drug release profiles**[58]**. Also, intrinsic fluorescence of the QDs allows real time observation of encapsulation efficiency and release dynamics using spectroscopic measurement methods, such as fluorescence spectroscopy and Förster resonance energy transfer (FRET). Taken together, the given qualities highlight the opportunities of QD-based delivery vehicles to reach controlled, effective, and traceable vonoprazan administration and, thus, justify the use of such technology in sophisticated nanomedicine and theranostic approaches**[59]**.



Figure 6. FRET-Based Drug Release Monitoring

6.1 Targeted Delivery: Surface Functionalization of QDs by Ligands/Antibodies.

Targeted drug delivery using quantum dots is a strategy that depends a lot on surface functionalization techniques that allow the selective interaction of the biological targets. QDs functionalized with ligands, peptide, or antibody has increased capacity to bind and receptor or biomarker on target cells or tissues, increasing site-specific drug localization and therapeutic activity. Modification on the surface is commonly achieved by covalent conjugation or adsorption with functional groups like amines, carboxyls or thiols, all of which can allow stable surface modification of the quantum dots without affecting the optical properties of the quantum dots**[60]**.

In the context of gastric drug delivery, ligands or antibodies directed against biomarkers associated with gastric mucosa or inflamed epithelial tissue can facilitate selective localization of Vonoprazan-loaded quantum dots. This targeted approach minimizes off-target distribution, reduces systemic exposure, and enhances local drug concentration at the site of action. Additionally, surface functionalization with biocompatible polymers such as polyethylene glycol (PEG) can further improve circulation stability, reduce nonspecific protein adsorption, and prolong residence time in the gastrointestinal tract. The combination of targeting ligands and quantum dot fluorescence also enables simultaneous therapeutic delivery and imaging, supporting theranostic applications. Overall, ligand- and antibody-functionalized quantum dots represent a promising strategy for achieving targeted, efficient, and traceable delivery of Vonoprazan in advanced nanomedicine systems**[61]**.

6.2 **The following are the advantages of QDs ligand/antibody functionalised: Increased target specificity:**

Functionalization of quantum dots (QDs) by a particular ligand or antibody has a number of benefits, the most noticeable one being a great specificity of targeted actions. Functionalized QDs can be used to localize the therapeutic payload to the location of action with accuracy by the specific recognition and binding to receptors or biomarkers on target tissues/cells. This increased specificity decreases nonspecific distribution and off-target effects thus enhancing the therapeutic efficacy and safety. Furthermore, focused binding also allows better local drug concentrations potentially tackling pharmacological efficacy and allowing reduced systemic doses. Targeting Ligandbased or antibodybased targeting additionally enhances cellular uptake via receptormediated endocytosis and thermal imaging and therapy due to inherent fluorescence of QDs. All these benefits contribute to the application of functionalized QDs as innovative nanocarriers in the application of nanomedicine in site-specific and traceable drug delivery**[62]**.

6.3 Imaging-Guided Therapy: QDs are Carriers and Bioimaging Agents.

Quantum dots are the best theranostic devices since they can be used as drug carriers and simultaneously as bioimaging agents. With vonoprazan therapy, QD-based systems are used to deliver the drug of interest and the localization and release behaviour of the drug are visualized in real-time. Such dual properties facilitate incorporation of both therapeutic and diagnostic functions in the same nanomedicine platform, hence it is affordable to have a precise control and monitoring of treatment results. Intrinsic fluorescence of QDs avoids invasive methods and any future monitoring of drug-loaded nanocarriers as it crosses the gastrointestinal tract and deposits at the target site, namely the gastric mucosa or Helicobacter pylori-infected tissues.

Real time feedback on therapeutic performance can be provided by correlating changes in fluorescence intensity or emission spectra with drug release and local microenvironmental conditions when vonoprazan is encapsulated within or conjugated to functionalized QDs. Specificity is further enhanced by surface engineering QDs with targeting ligands or antibodies which allow specific binding to diseased tissues or pathogens, thereby enhancing the accuracy with which the localization of the defined target can be controlled and reducing off-target effects. QD fluorescence-mediated imaging-guided therapy allows the assessment of the pharmacokinetics and pharmacodynamics simultaneously and, as a result, the optimization of dosing protocols and personal treatment plans. In addition, the QD-based theranostic systems have potential of minimizing the systemic side effects as vonoprazan is controlled to be released at the specific location of action required. Even though issues with cytotoxicity of heavy-metal based QDs are present, the creation of safer alternatives (carbon-, graphene-, silicon based quantum dots) can present a good solution without affecting optical characteristics. Multifunctional QD platforms in the future, combining drug delivery, imaging, and microenvironmental sensing and AI-assisted spectral analysis, can further improve real-time monitoring, precision of the therapeutic intervention, and clinical outcomes in the treatment of acid-related gastrointestinal diseases**[63]**.

VII. Quantum Dots Toxicity and Biocompatibility:

7.1 Cytotoxicity problems of heavy-metal-based QDs (Cd, Pb).

Quantum dots made of heavy metals like cadmium and lead have been widely researched because they possess outstanding luminescence, emission wavelengths that can be tuned and high photostability. Although these have these beneficial optical characters, they cannot be used in biomedical and clinical applications due to the issue of cytotoxicity. QDs based on heavy metals tend to release toxic metal ions in physiological or environmental situations, which may cause the formation of reactive oxygen species and subsequently cause oxidative stress, DNA damage, cellular apoptosis and inflammatory

conditions**[64]**. In vivo experiments have shown that Cd 205 and Pb 205 based QDs can be localized in vital organs, such as the liver, kidneys and spleen leading to chronic toxicity and dysfunction of the organ. The degree of cytotoxicity is highly dependent on several factors which include the particle size, the surface chemistry, dosage, route of administration and the period of exposure. Smaller size and incompatible surfaces are more likely to be toxic due to the larger ion release and uptake in the cells. These safety issues significantly restrict the translational utility of heavy-metal QDs in drug delivery and theranostic practice and importantly, careful material design, surface optimization, and thorough toxicological testing must be considered during the development of QD-based drug delivery platforms**[65]**.

7.2 Alternatives: The alternatives to safer probes are Carbon Dots, Graphene Dots and Silicon QDs.

To overcome the cytotoxicity of heavy-metal QDs, scientists have made non-metallic quantum dots including carbon dots, graphene quantum dots and silicon QDs. Such nanomaterials can be used in biomedical applications such as drug delivery and imaging due to their lack of toxicity to cells, biocompatibility, fluorescence and being easily soluble in aqueous media. Under no condition of any modification or alteration of the carbon and graphene dots, the different ligands or therapeutic molecules can be conjugated without any adverse effects. In particular, silicon QDs are biodegradable, and have low long-term toxicity. These less lethal versions maintain the optical benefits of the conventional QDs but makes them more practical in clinical and in vivo**[66]**.

7.3 Techniques to coating surfaces in order to make them less toxic.

Surface engineering is one of the methods that can be used in order to reduce the toxicity of QDs. The heavy-metal ions are blocked by coating QDs using biocompatible polymers like polyethylene glycol, silica or lipid layers and increases the aqueous solubility, thus stabilizing them in the body. The surface coatings can also be functional groups that conjugate with drugs or targeting ligands that can enable drug delivery to be safe and effective. The fact that encapsulation in polymeric or lipid shells reduces cytotoxicity, increases circulation time, controls release, and enhances targeting efficiency, serves as proof of these advantages. Therefore, the coated QDs are beneficial in the delivery of agents like vonoprazan with few side effects**[67]**.



Figure 7. Toxicity Comparison of Quantum Dots

VIII.Regulatory Implications of Nanomaterial Drug Delivery Systems.

Specific concerns have been reported by regulatory bodies to be involved in the clinical translation of nanomaterial-based drug delivery systems, especially those delivered by the systemic or repeated routes. The physical and chemical properties of nanomaterials are size dependent as compared to conventional pharmaceuticals and can have unpredictable effects on biological interactions,

biodistribution, and toxicity profiles. As a result, to regulate nanomedicines, in-depth characterization of nanomedicines is needed beyond the usual pharmacokinetic and toxicological studies**[68]**.

It is also important that long clearance and biodegradation routes of nanocarriers are questioned. The regulatory agencies have stressed the need to show effective excretion of the nanomaterials out of the organism or rather its persistence over long durations, which may result in bioaccumulation and delayed toxicity. Longitudinal studies are necessary to identify the routes of elimination renally, by metabolism in the liver, or by biodegradation to non-toxic metabolites**[68]**.

Biodistribution studies are also another important need, because nanomaterials can be deposited in non-target organs such as the liver, spleen, kidneys, lungs, and others. To determine tissue allocation, retention kinetics and organ-specific accumulation after administration, regulatory bodies are compelled to use detailed in vivo imaging along with quantitative measures. These data are essential in the assessment of the therapeutic efficacy as well as likely long-term toxicity**[69]**.

Among the most crucial regulatory requirements entails arduous profiling of toxicity, which includes acute, sub-chronic, and chronic tests. The cytotoxicity, oxidative stress, immunogenicity and possible genotoxic effects are of particular concern in quantum-dot-based systems**[70]**. Such assessments should incorporate the variables of particle size, surface chemistries, dose delivered, and exposure time since nanomaterial toxicity may largely differ to the toxicity of the unconjugated therapeutic agent. Besides, the release of the toxic ions of heavy-metal-based quantum dots is a serious security issue to the regulatory bodies**[71]**.

Under this regulatory mechanism, carbon and silicon-based quantum dots are regarded as less problematic alternatives to the heavy-metal-based quantum dots. They have desirable biocompatibility, reduced cytotoxicity and mitigated release of metal ions, which grants them better safety profiles**[72]**. In particular, silicon quantum dots can be hydrolytically converted into non-toxic silicic acid, and carbon quantum dots can be hydrolytically converted into carbonic acid that has favourable clearance dynamics and insignificant long-term tissue deposition. These features are in tandem with safety, environmental compatibility, and clinical feasibility requirements of regulatory bodies like the FDA and EMA, which will boost the translational potential of QD based Vonoprazan nanomedicine systems, and lend them momentum towards regulatory approval and clinical use**[73]**.

QD Nanomedicine Vonoprazan.

8.1AI/ML assisted QD -based Spectroscopy.

The combination of quantum-dot-based spectroscopy with artificial intelligence and machine-learning (AI/ML) is one of the opportunities of the further development of Vonoprazan nanomedicine. Quantum-dot spectroscopy provides complicated datasets of fluorescence, emission spectral shifts, and Förster resonance energy transfer (FRET) interactions, challenging to solve by other analytical methods. These data can be processed effectively by AI/ML in order to predict the drug release kinetics, identify the patterns in the interaction between drugs and nanocarriers, and optimise nanocarrier architecture. In turn, real time monitoring and predictive modelling are also speeded up through data-driven platforms, thus streamlining the optimisation of more accurate and tailored Vonoprazan delivery systems**[74]**.

8.2 Individualized Vonoprazan Therapy with Safer Quantum Dots.

Individualized vonoprazan therapy is a prospect, which will depend on the implementation of biocompatible quantum dots, which will reduce toxicity without affecting optical functionality. Graphene, silicon quantum dots, and carbon quantum dots have also emerged as alternatives to heavy-metal-based quantum dots, and offer less cytotoxicity, chemical stability and tunable fluorescence. They have favorable surface chemistries, which enable them to efficiently

encapsulate drugs, target delivery, and extend imaging times, which in turn make them ideal in the establishment of patient-specific dosing paradigms. Such resources provide a regulatory-friendly framework of individualised nanomedicine projects**[75]**.

8.3 QD vonoprazan nanomedicine clinical translation.

QD-based Vonoprazan delivery systems have a significant potential to reduce the acid-induced gastroenterological conditions due to the improved targeting, regulated delivery time, and real-time therapy monitoring. Selective localisation of surface engineered quantum dots to gastric mucosa or Helicobacter pylori infected areas can enhance these local concentrations of drugs and reduce systemic diffusion. Their natural fluorescence also gives them theranostic features, allowing combined drug delivery and imaging based assessment of pharmacodynamics and pharmacokinetics. Regarding the enormous challenges faced in regard to the large scale fabrication, long term safety, and regulatory acceptance, it is expected that progressive advances in nanofabrication methods and modification of surface chemistry would simplify the clinical translation of the QD based Vonoprazan nanomedicine**[76]**.

IX. Multifunctional nanocarriers: delivery to imaging to monitoring.

The paradigm shift in nanomedicine Multifunctional nanocarriers are epitomised as a combination of drug delivery, bioimaging, and therapeutic surveillance in one construct. The quantum-dot nanocarriers are the embodiment of this vision because they allow delivering Vonoprazan to gastrointestinal locations at the same time inducing real-time optical emissions that can be used to visualize drug localisation, distribution, and release kinetics. Surface conjugation or encapsulation of Vonoprazan into quantum dots yields better stability of the drug, higher solubility, and controlled release, which improves treatment response and reduces the off-target effects**[76]**.



Figure 8. Theranostic Concept

X.The QD-based spectroscopy on vonoprazan studies is beneficial in numerous aspects.

Quantum-dot-based spectroscopy is giving significant benefits in Vonoprazan studies in nanomedicine and advanced drug-delivery systems**[77]**. The highly sensitive detection of quantum dots at sub-micromolar concentrations due to its strong and tunable fluorescence provides the ability to measure the drug encapsulation efficiencies, release kinetics, and drug-nanocarrier interaction under in-vitro and in-vivo requirements. These non-destructive spectroscopic modalities have the inherent ability to observe real-time dynamic release and transport processes of drugs**[78]**. Also, quantum dots can be imaged simultaneously with other optical imaging techniques since they have inherent optical properties that allow the spatial localization of Vonoprazan distribution inside and outside cellular, tissue, and compartments of the gastric mucosa**[79]**.

More complex modes of nanoscale interrogation of carrier-drug interactions, including fluorescence mapping and Förster resonance energy transfer (FRET), overcome some of the key limitations of the traditional chromatographic approaches**[80]**.

Nanotechnology holds a central position in the enhancement of Vonoprazan drug delivery to a higher level of stability, targeting, and medical control. Quantum dots, polymeric nanoparticles and lipid-based systems, known as nanocarriers, protect Vonoprazan against early degradation and small bowel fluctuations, which ultimately leads to improved and more predictable absorption. Nanocarriers that have been surface-engineered induce targeted delivery to gastric mucosa or Helicobacter pylori sites, which increase the concentration of drugs in the region and reduce their systemic exposure. Also, the maintenance of therapeutic-thresholds and the reduced dosing frequency are also possible due to the controlled and sustained drug release. In quantum-dot-based systems, integrated fluorescence facilitates combined drug delivery and imaging and, therefore, real-time evaluation of the pharmacokinetic and pharmacodynamic parameters. All these nanotechnological schemes significantly improve the treatment and translational capabilities of Vonoprazan-based therapies**[81]**.

XI. Clinical Translation and Perspectives.

The therapeutic application of quantum-dot (QD)-based Vonoprazan nanomedicine requires a careful balance of safety considerations, scalability, and regulatory safety**[82]**. The use of biocompatible resources including carbon- and silicon-based QDs has enhanced the translational capacity by allaying the toxicological apprehension**[83]**. QD-based delivery vehicles have multi-dimensional benefits, such as gastric-targeted localization, controlled pharmacokinetic release, and theranostic capabilities to monitor in real-time, all of which improve the therapeutic outcomes and provide the opportunity to support personalized dosing schedules**[84]**.

Nevertheless, barriers of large-scale production, longitudinal safety testing, reproducibility, and harmonization of regulatory standards remain great barriers to clinical integration. The future studies should focus on designing biodegradable QD systems, standardized systems of synthetic procedures, and improved surface engineering measures. The inclusion of artificial-intelligence-enhanced analytical procedures can also optimize the nanocarrier structure and make the translation processes faster. Through a long-term interdisciplinary partnership and regulatory strategy, QD based Vonoprazan nanomedicine has the potential to aid the development of precision therapeutics in acid related gastrointestinal diseases**[84]**.

XII. Conclusion

The review highlights the emerging role of QD based nanotechnology in the improvement of analytical properties and delivery of Vonoprazan to acid related gastrointestinal disorders. Younger combination of QD-based spectroscopy with nanocarrier-based drug delivery conveys unique merits with respect to traditional analytical and formulation models, which include increased sensitivity, sustained monitoring, gastric targeting, and thermostatic combination. Through the combination of these properties, there is an enhancement of stability, bioavailability and treatment accuracy of drugs which are deemed as the main limitations of the traditional Vonoprazan formulations and modalities of analysis.

Notwithstanding these promising features, the effective clinical translation of these systems requires stringent thinking in regard to biocompatibility, durability of safety, scalability of manufacturing and standardization of regulatory aspects. The shift to the safer QD technology, especially on carbon, graphene and silicon basis has significantly amplified the translation of feasibility by dampening the toxicity risks and increasing biodegradability. It will be necessary to continuously optimize surface-engineering procedures and introduce a standardized assessment protocol in order to achieve reproducibility and clinical reliability.

When examining the future, it is expected that, in the combination of QD nanotechnology with a strong surface modification approach, biodegradable nanomaterials, and AI-assisted data analytics, Vonoprazan nanomedicine would get refined further. This kind of interdisciplinary development can facilitate individualized treatment through the real-time tracking of the drug distribution and release dynamics. As further investigations and regulatory harmonization are made, QD-based Vonoprazan nanomedicine has a significant potential to become precision gastroenterology and next-generation therapeutic approaches.

XIII. ACKNOWLEDGMENT

The authors would like to thank the School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Studies, Chennai for their technical support.

REFERENCES

1) Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R. The Montreal definition and classification of gastroesophageal reflux disease. *Am J Gastroenterol.* 2006;101(8):1900–20.
2) Sachs G, Shin JM, Howden CW. Review article: the clinical pharmacology of proton pump inhibitors. *Aliment Pharmacol Ther.* 2006;23(Suppl 2):2–8.
3) Furuta T, Shirai N, Sugimoto M. Pharmacogenomics of proton pump inhibitors. *Pharmacogenomics.* 2004;5(2):181–202.
4) Robinson M, Horn J. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know. *Drugs.* 2003;63(24):2739–54.
5) Hori Y, Imanishi A, Matsukawa J, et al. TAK-438 (vonoprazan), a novel potassium-competitive acid blocker. *J Pharmacol Exp Ther.* 2010;335(1):231–38.
6) Ashida K, Sakurai Y, Hori T, et al. Randomised clinical trial: vonoprazan vs lansoprazole for erosive oesophagitis. *Aliment Pharmacol Ther.* 2016;43(2):240–51.
7) Kagami T, Sahara S, Ichikawa H, et al. Potent acid inhibition by vonoprazan in PPI-resistant GERD. *Clin Gastroenterol Hepatol.* 2016;14(3):430–37.
8) Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. *Science.* 2004;303(5665):1818–22.
9) Medintz IL, Uyeda HT, Goldman ER, Mattoussi H. Quantum dot bioconjugates for imaging, labeling and sensing. *Nat Mater.* 2005;4:435–46.
10) Wegner KD, Hildebrandt N. Quantum dots: bright and versatile in vitro and in vivo fluorescence imaging biosensors. *Chem Soc Rev.* 2015;44:4792–834.
11) Lakowicz JR. *Principles of Fluorescence Spectroscopy.* 3rd ed. New York: Springer; 2006.
12) Sachs G, Shin JM, Howden CW. Review article: the clinical pharmacology of proton pump inhibitors and potassium-competitive acid blockers. *Aliment Pharmacol Ther.* 2006;23(Suppl 2):2–8.
13) Garnock-Jones KP. Vonoprazan: first global approval. *Drugs.* 2015;75(4):439–43.
14) Medintz IL, Uyeda HT, Goldman ER, Mattoussi H. Quantum dot bioconjugates for imaging, labelling and sensing. *Nat Mater.* 2005;4:435–46.
15) Lakowicz JR. *Principles of Fluorescence Spectroscopy.* 3rd ed. New York: Springer; 2006.
16) Wegner KD, Hildebrandt N. Quantum dots: bright and versatile in vitro and in vivo fluorescence imaging biosensors. *Chem Soc Rev.* 2015;44:4792–834.
17) Mura S, Couvreur P. Nanotheranostics for personalized medicine. *Adv Drug Deliv Rev.* 2012;64(13):1394–416.

18) Hori Y, Imanishi A, Matsukawa J, et al. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine (TAK-438), a novel potassium-competitive acid blocker. *J Pharmacol Exp Ther.* 2010;335(1):231–38.
19) Scott DR, Munson KB, Marcus EA, Lambrecht NW, Sachs G. The binding of vonoprazan to H^+/K^+-ATPase. *Biochem Pharmacol.* 2015;96(3):244–51.
20) Garnock-Jones KP. Vonoprazan: first global approval. *Drugs.* 2015;75(4):439–43.
21) Sakurai Y, Nishimura A, Kennedy G, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of single rising TAK-438 doses in healthy male subjects. *Aliment Pharmacol Ther.* 2015;41(7):636–48.
22) Garnock-Jones KP. Vonoprazan: first global approval. *Drugs.* 2015;75(4):439–43.
23) Hardman R. A toxicologic review of quantum dots: toxicity depends on physicochemical and environmental factors. *Environ Health Perspect.* 2006;114(2):165–72.
24) Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. *Science.* 2004;303(5665):1818–22.
25) Lakowicz JR. *Principles of Fluorescence Spectroscopy.* 3rd ed. New York: Springer; 2006.
26) Etheridge ML, Campbell SA, Erdman AG, et al. The big picture on nanomedicine: the state of investigational and approved nanomedicine products. *Nanomedicine.* 2013;9(1):1–14.
27) Garnock-Jones KP. Vonoprazan: first global approval. *Drugs.* 2015;75(4):439–43.
28) Hori Y, Imanishi A, Matsukawa J, et al. TAK-438, a novel potassium-competitive acid blocker. *J Pharmacol Exp Ther.* 2010;335(1):231–38.
29) Sakurai Y, Nishimura A, Kennedy G, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of TAK-438 in healthy subjects. *Aliment Pharmacol Ther.* 2015;41(7):636–48.
30) Ashida K, Sakurai Y, Nishimura A, et al. Vonoprazan vs lansoprazole for erosive oesophagitis: randomized clinical trial. *Aliment Pharmacol Ther.* 2016;43(2):240–51.
31) Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. *Science.* 2004;303(5665):1818–22.
32) Medintz IL, Uyeda HT, Goldman ER, Mattoussi H. Quantum dot bioconjugates for imaging, labeling and sensing. *Nat Mater.* 2005;4:435–46.
33) Algar WR, Massey M, Krull UJ. The application of quantum dots to diagnostics. *Anal Bioanal Chem.* 2009;391:1609–18.
34) Lakowicz JR. *Principles of Fluorescence Spectroscopy.* 3rd ed. New York: Springer; 2006.
35) Hardman R. A toxicologic review of quantum dots: toxicity depends on physicochemical and environmental factors. *Environ Health Perspect.* 2006;114(2):165–72.
36) Alivisatos AP. Semiconductor clusters, nanocrystals, and quantum dots. *Science.* 1996;271(5251):933–37.
37) Medintz IL, Uyeda HT, Goldman ER, Mattoussi H. Quantum dot bioconjugates for imaging, labeling and sensing. *Nat Mater.* 2005;4:435–46.
38) Hardman R. A toxicologic review of quantum dots: toxicity depends on physicochemical and environmental factors. *Environ Health Perspect.* 2006;114(2):165–72.
39) Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. *Science.* 2004;303(5665):1818–22.
40) Medintz IL, Uyeda HT, Goldman ER, Mattoussi H. Quantum dot bioconjugates for imaging, labeling and sensing. *Nat Mater.* 2005;4:435–46.
41) Wegner KD, Hildebrandt N. Quantum dots: bright and versatile in vitro and in vivo fluorescence imaging biosensors. *Chem Soc Rev.* 2015;44:4792–834.
42) Medintz IL, Uyeda HT, Goldman ER, Mattoussi H. Quantum dot bioconjugates for imaging, labeling and sensing. *Nat Mater.* 2005;4:435–46.
43) Hardman R. A toxicologic review of quantum dots: toxicity depends on physicochemical and environmental factors. *Environ Health Perspect.* 2006;114(2):165–72.
44) Skoog DA, Holler FJ, Crouch SR. *Principles of Instrumental Analysis.* 6th ed. Belmont: Thomson Brooks/Cole; 2007.
45) Lakowicz JR. *Principles of Fluorescence Spectroscopy.* 3rd ed. New York: Springer; 2006.
46) Medintz IL, Uyeda HT, Goldman ER, Mattoussi H. Quantum dot bioconjugates for imaging, labeling and sensing. *Nat Mater.* 2005;4:435–46.
47) Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. *Science.* 2004;303(5665):1818–22.

48) Skoog DA, Holler FJ, Crouch SR. *Principles of Instrumental Analysis.* 6th ed. Belmont: Thomson Brooks/Cole; 2007.
49) Lakowicz JR. *Principles of Fluorescence Spectroscopy.* 3rd ed. New York: Springer; 2006.
50) Medintz IL, Uyeda HT, Goldman ER, Mattoussi H. Quantum dot bioconjugates for imaging, labeling and sensing. *Nat Mater.* 2005;4:435–46.
51) Förster T. Zwischenmolekulare Energiewanderung und Fluoreszenz. *Ann Phys.* 1948;437:55–75.
52) Medintz IL, Uyeda HT, Goldman ER, Mattoussi H. Quantum dot bioconjugates for imaging, labeling and sensing. *Nat Mater.* 2005;4:435–46.
53) Lakowicz JR. *Principles of Fluorescence Spectroscopy.* 3rd ed. New York: Springer; 2006.
54) Medintz IL, Uyeda HT, Goldman ER, Mattoussi H. Quantum dot bioconjugates for imaging, labeling and sensing. *Nat Mater.* 2005;4:435–46.
55) Algar WR, Massey M, Krull UJ. The application of quantum dots to diagnostics. *Anal Bioanal Chem.* 2009;391:1609–18.
56) Garnock-Jones KP. Vonoprazan: first global approval. *Drugs.* 2015;75(4):439–43.
57) Medintz IL, Uyeda HT, Goldman ER, Mattoussi H. Quantum dot bioconjugates for imaging, labeling and sensing. *Nat Mater.* 2005;4:435–46.
58) Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. *Science.* 2004;303(5665):1818–22.
59) Medintz IL, Uyeda HT, Goldman ER, Mattoussi H. Quantum dot bioconjugates for imaging, labeling and sensing. *Nat Mater.* 2005;4:435–46.
60) Medintz IL, Uyeda HT, Goldman ER, Mattoussi H. Quantum dot bioconjugates for imaging, labeling and sensing. *Nat Mater.* 2005;4:435–46.
61) Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. *Science.* 2004;303(5665):1818–22.
62) Medintz IL, Uyeda HT, Goldman ER, Mattoussi H. Quantum dot bioconjugates for imaging, labeling and sensing. *Nat Mater.* 2005;4:435–46.
63) Medintz IL, Uyeda HT, Goldman ER, Mattoussi H. Quantum dot bioconjugates for imaging, labeling and sensing. *Nat Mater.* 2005;4:435–46.
64) Hardman R. A toxicologic review of quantum dots: toxicity depends on physicochemical and environmental factors. *Environ Health Perspect.* 2006;114(2):165–72.
65) Derfus AM, Chan WCW, Bhatia SN. Probing the cytotoxicity of semiconductor quantum dots. *Nano Lett.* 2004;4(1):11–18.
66) Lim SY, Shen W, Gao Z. Carbon quantum dots and their applications. *Chem Soc Rev.* 2015;44:362–81.
67) Derfus AM, Chan WCW, Bhatia SN. Probing the cytotoxicity of semiconductor quantum dots. *Nano Lett.* 2004;4(1):11–18.
68) European Medicines Agency. *Reflection paper on nanotechnology-based medicinal products for human use.* London: EMA; 2011.
69) Fadeel B, Farcal L, Hardy B, et al. Advanced tools for the safety assessment of nanomaterials. *Nat Nanotechnol.* 2018;13:537–43.
70) Iavicoli I, Leso V, Fontana L, Bergamaschi A. Toxicological effects of nanomaterials: a review. *Toxicol Mech Methods.* 2011;21(7):513–25.
71) Nel A, Xia T, Mädler L, Li N. Toxic potential of materials at the nanolevel. *Science.* 2006;311(5761):622–27.
72) Li H, Kang Z, Liu Y, Lee ST. Carbon nanodots: synthesis, properties and applications. *J Mater Chem.* 2012;22:24230–53.
73) Park JH, Gu L, von Maltzahn G, et al. Biodegradable luminescent porous silicon nanoparticles for in vivo applications. *Nat Mater.* 2009;8:331–36.
74) Zhou ZH, Chen Y, Li Y. Machine learning in nanomedicine: opportunities and challenges. *ACS Nano.* 2019;13(8):8649–56
75) Mura S, Couvreur P. Nanotheranostics for personalized medicine. *Adv Drug Deliv Rev.* 2012;64(13):1394–416.
76) Janib SM, Moses AS, MacKay JA. Imaging and drug delivery using theranostic nanoparticles. *Adv Drug Deliv Rev.* 2010;62(11):1052–63.
77) Resch-Genger U, Grabolle M, Cavaliere-Jaricot S, Nitschke R, Nann T. Quantum dots versus organic dyes as fluorescent labels. *Nat Methods.* 2008;5(9):763–75.

78) Algar WR, Tavares AJ, Krull UJ. Beyond labels: a review of the application of quantum dots as integrated components of assays, bioprobes, and biosensors. *Anal Chim Acta.* 2010;673(1):1–25.
79) Michalet X, Pinaud FF, Bentolila LA, et al. Quantum dots for live cells, in vivo imaging, and diagnostics. *Science.* 2005;307(5709):538–44.
80) Medintz IL, Clapp AR. Potential clinical applications of quantum dots. *Int J Nanomedicine.* 2008;3(2):151–67.
81) Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. *Nat Rev Cancer.* 2017;17:20–37.
82) Duncan R, Gaspar R. Nanomedicine(s) under the microscope. *Mol Pharm.* 2011;8(6):2101–41.
83) McVey BF, Tilley RD. Solution synthesis, optical properties, and bioimaging applications of silicon nanocrystals. *Acc Chem Res.* 2014;47(10):3045–51.
84) He X, Hwang HM. Nanotechnology in food science: functionality, applicability, and safety assessment. *J Food Drug Anal.* 2016;24(4):671–81.

-